[
  {
    "ts": null,
    "headline": "Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run",
    "summary": "Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.",
    "url": "https://finnhub.io/api/news?id=2e4ce4b58d5499c9f69dd8adc9b256ea731f4941a33cad7ee4c9e950768aada7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760824800,
      "headline": "Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run",
      "id": 137155101,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1189813806/image_1189813806.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.",
      "url": "https://finnhub.io/api/news?id=2e4ce4b58d5499c9f69dd8adc9b256ea731f4941a33cad7ee4c9e950768aada7"
    }
  },
  {
    "ts": null,
    "headline": "A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results",
    "summary": "Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS Conference and the European Society for Medical Oncology. Updates include HIV treatment advances and important data from cancer trials. See our latest analysis for Gilead Sciences. After unveiling positive data at major scientific conferences, Gilead Sciences is enjoying a notable run, with its share price climbing nearly 34% year-to-date and delivering an impressive 1-year...",
    "url": "https://finnhub.io/api/news?id=134497b47a4811520c4b3a0e2005bb6205a2e1740b91837a95c6f24ea35ba844",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760750217,
      "headline": "A Look at Gilead Sciences’s Valuation Following Breakthrough HIV and Cancer Clinical Trial Results",
      "id": 137164518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS Conference and the European Society for Medical Oncology. Updates include HIV treatment advances and important data from cancer trials. See our latest analysis for Gilead Sciences. After unveiling positive data at major scientific conferences, Gilead Sciences is enjoying a notable run, with its share price climbing nearly 34% year-to-date and delivering an impressive 1-year...",
      "url": "https://finnhub.io/api/news?id=134497b47a4811520c4b3a0e2005bb6205a2e1740b91837a95c6f24ea35ba844"
    }
  }
]